ArticleGut and liver2012
Rifaximin Plus Levofloxacin-Based Rescue Regimen for the Eradication of Helicobacter pylori.
Article in Gut and liver, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Treatment of Helicobacter pylori Infection in Korea: A Systematic Review and Meta-analysis.Journal of Korean medical science · 2015Pooled it
- Seven-day quintuple regimen as a rescue therapy for Helicobacter pylori eradication.World journal of gastroenterology · 2015Trial
- Effectiveness and Safety of Rifaximin-Containing Regimens forInfection and drug resistance · 2022Review
- Management of Helicobacter pylori infection: The Bhubaneswar Consensus Report of the Indian Society of Gastroenterology.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2021Article
- Article
- Current Status of the Third-LineGastroenterology research and practice · 2018Review
- Therapeutic efficacy of amoxicillin and rifaximin in patients with small intestinal bacterial overgrowth andPrzeglad gastroenterologiczny · 2018Article
- Efficacy of Levofloxacin-Based Third-Line Therapy for the Eradication ofGut and liver · 2017Article
- Rescue Therapy with a Proton Pump Inhibitor Plus Amoxicillin and Rifabutin for Helicobacter pylori Infection: A Systematic Review and Meta-Analysis.Gastroenterology research and practice · 2015Review
- Helicobacter pylori: evidence-based review with a focus on immigrant populations.Journal of general internal medicine · 2014Review
- Second and third line treatment options for Helicobacter pylori eradication.World journal of gastroenterology · 2014Review
- Spontaneous bacterial peritonitis by Pasteurella multocida under treatment with rifaximin.Infection · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsThis study assessed the efficacy of a rifaximin plus levofloxacin-based rescue regimen in patients that had failed both triple and quadruple standard regimens for the eradication of Helicobacter pylori.
methodsWe treated patients for H. pylori between August 2009 and April 2011. The triple regimen consisted of combined treatment with amoxicillin, clarithromycin, and pantoprazole for 1 week. For failed cases, a quadruple regimen of tetracycline, metronidazole, bismuth dicitrate, and lansoprazole for 1 week was administered. The rescue regimen for persistently refractory cases was rifaximin 200 mg t.i.d., levofloxacin 500 mg q.d., and lansoprazole 15 mg b.i.d. for 1 week.
resultsIn total, 482 patients were enrolled in this study. The eradication rates associated with the first and second regimens were 58% and 60%, respectively. Forty-seven out of 58 patients who failed with the second-line regimen received rifaximin plus levofloxacin-based third-line therapy. The eradication rate for the third regimen was 65%. The cumulative eradication rates were 58%, 85%, and 96% for each regimen, respectively.
conclusionsA rifaximin plus levofloxacin-based regimen could be an alternative rescue therapy in patients with resistance to both triple and quadruple regimens for the eradication of H. pylori.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.